CEO's $2M planned sale is notable but not alarming; monitor whether the sale actually executes and at what price. Institutional accumulation suggests long-term conviction remains intact. Watch for any unexpected news or trial readouts before assuming insider pessimism — biotech CEO sales are often part of routine tax/estate planning.
Price Chart
Executive Summary
CEO Jon Congleton files Form 144 to sell 75,000 shares valued at ~$1.96M, sourced from RSU vestings. The planned sale is modest relative to the $2.2B market cap and his likely total holdings, but the ~$2.0M cash-out by the CEO is notable in light of Institutional 13F accumulation (8 adds, 1 new) and the lack of recent positive catalysts.
Key Facts
- Insider: Jon Congleton, CEO of Mineralys Therapeutics, filed Form 144 on 6/30/2026 to sell 75,000 shares of common stock.
- Estimated proceeds: ~$1,960,602 at filing (approx. $26.14/share based on recent trade data).
- Shares to be sold were acquired through vesting of RSU awards on 7/10/2024 (24,619 shares), 10/10/2024 (35,954 shares), and 1/10/2025 (14,427 shares).
- Congleton also received a separate RSU award of 75,000 shares on 3/31/2026 and additional shares on 4/13/2026.
- Form 144 is an advance intent to sell; the actual sale may not occur.
- Recent insider activity (30d): 3 other sells totaling $425K.
- Institutional 13F mostly supportive: 8 adds, 1 new, 4 doubled, 4 trims, 1 exit.
- Prior model calls on MLYS have been highly inaccurate (avg T+20 P&L -10.79%, 0% win rate).
Financial Impact
CEO selling ~$2.0M of stock, representing about 0.09% of market cap
Risk Factors
- CEO selling ahead of potential negative catalyst not yet disclosed
- Form 144 allows sale but may not execute — uncertainty on actual timing and volume
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000303 |
| Document: 0001964306-26-000303-index.html | 0001964306-26-000303 |
| Document: 0001964306-26-000303.txt | 0001964306-26-000303 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 3 | $26.09 $28.20 | ▲ +8.09% | ▲ +9.83% | $23.56 (−9.70%) |
Jul 23, 2026 10w ago | Insider Cluster | $26.71 $25.65 | ▼ −3.97% | ▼ −7.59% | $23.56 (−11.79%) |
Jul 21, 2026 10w ago | Insider Cluster | $27.52 $26.61 | ▼ −3.31% | ▼ −5.87% | $23.56 (−14.39%) |
Jul 16, 2026 11w ago | Insider Cluster | $27.08 $26.09 | ▼ −3.66% | ▼ −7.27% | $23.56 (−13.00%) |
Jun 30, 2026 13w ago | 144 | $26.89 $26.35 | ▼ −2.01% | ▲ +0.18% | $23.56 (−12.38%) |
Jun 29, 2026 13w ago | 144 | $26.88 $26.71 | ▼ −0.63% | ▼ −0.35% | $23.56 (−12.35%) |
Jun 18, 2026 15w ago | Insider Cluster | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 17, 2026 15w ago | 144 | $24.63 $27.08 | ▲ +9.95% | ▲ +9.41% | $23.56 (−4.34%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.94 $28.96 | ▲ +20.97% | ▲ +19.08% | $23.56 (−1.59%) |
Jun 3, 2026 17w ago | 8-K | $25.06 $27.69 | ▲ +10.49% | ▲ +11.49% | $23.56 (−5.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access